This HTML5 document contains 113 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n14https://global.dbpedia.org/id/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
provhttp://www.w3.org/ns/prov#
dbchttp://dbpedia.org/resource/Category:
dbphttp://dbpedia.org/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Infectious_causes_of_cancer
dbo:wikiPageWikiLink
dbr:Fibrin-associated_diffuse_large_B-cell_lymphoma
Subject Item
dbr:Diffuse_large_B-cell_lymphoma_associated_with_chronic_inflammation
dbo:wikiPageWikiLink
dbr:Fibrin-associated_diffuse_large_B-cell_lymphoma
Subject Item
dbr:B-cell_lymphoma
dbo:wikiPageWikiLink
dbr:Fibrin-associated_diffuse_large_B-cell_lymphoma
Subject Item
dbr:Fibrin-associated_diffuse_large_B-cell_lymphoma
rdf:type
dbo:Disease wikidata:Q12136 owl:Thing
rdfs:label
Fibrin-associated diffuse large B-cell lymphoma
rdfs:comment
Fibrin-associated diffuse large B-cell lymphoma (FA-DLBCL) is an extremely rare form of the diffuse large B-cell lymphomas (DLBCL). DLBCL are lymphomas in which a particular type of lymphocyte, the B-cell, proliferates excessively, invades multiple tissues, and often causes life-threatening tissue damage. DLBCL have various forms as exemplified by one of its subtypes, diffuse large B-cell lymphoma associated with chronic inflammation (DLBCL-CI). DLBCL-CI is an aggressive malignancy that develops in sites of chronic inflammation that are walled off from the immune system. In this protected environment, the B-cells proliferate excessively, acquire malignant gene changes, form tumor masses, and often spread outside of the protected environment. In 2016, the World Health Organization provision
foaf:name
Fibrin-associated diffuse large B-cell lymphoma
dbp:name
Fibrin-associated diffuse large B-cell lymphoma
dcterms:subject
dbc:Lymphoma dbc:Non-Hodgkin_lymphoma
dbo:wikiPageID
63408853
dbo:wikiPageRevisionID
1054174567
dbo:wikiPageWikiLink
dbr:Fibrin dbr:Chemotherapy dbr:Asymptomatic_carrier dbr:Lymphoproliferative_disorders dbr:Embolism dbr:Brain dbr:Plasma_cell dbc:Lymphoma dbr:Prednisolone dbr:MUM1 dbr:Foreign_body dbr:Asymptomatic dbr:Epstein-Barr_virus-associated_lymphoproliferative_diseases dbr:Adaptive_immune_system dbr:Hydrocele_testis dbr:Epstein-Barr_virus dbr:Clotting_factor dbr:Malignant dbr:P53 dbr:Cardiac_myxoma dbr:Malignancy dbr:Endothelium dbr:Arachnoid_mater dbr:Rituximab dbr:Hematoma dbr:PAX5 dbr:CD30 dbr:White_blood_cell dbr:Non-specific_symptoms dbr:Joint_replacement dbr:CD79a dbr:Epstein–Barr_virus-associated_lymphoproliferative_diseases dbr:Virus_latency dbr:MYC dbr:Strokes dbr:Testicle dbr:Infectious_mononucleosis dbr:Hematology dbr:CHOP_(chemotherapy) dbr:Diffuse_large_B-cell_lymphoma_associated_with_chronic_inflammation dbr:Cyclophosphamide dbr:CD45 dbr:Histology dbr:Cyst dbr:Tunica_vaginalis dbc:Non-Hodgkin_lymphoma dbr:Oncology dbr:Cytotoxic_T-cells dbr:B-cell dbr:Prednisone dbr:Thrombus dbr:Retroperitoneum dbr:Chronic_inflammation dbr:Lymphomas dbr:Radiotherapy dbr:Oncovin dbr:Meninges dbr:Atrium_(heart) dbr:Adrenal_gland dbr:Histological dbr:Diffuse_large_B-cell_lymphoma dbr:Pseudocyst dbr:Implant_(medicine) dbr:Vascular_system dbr:Immune_system dbr:PD-L1 dbr:Lymphocyte dbr:Dura_mater dbr:Subdural_hematoma dbr:Hydroxydaunorubicin dbr:CD20 dbr:Connective_tissue dbr:Body_cavity dbr:Myxoid_tumor dbr:Stent dbr:Thrombi dbr:Artificial_heart_valve dbr:Immunohistochemistry dbr:Fibrinogen dbr:Cysts dbr:Epithelium dbr:World_Health_Organization dbr:Virus
owl:sameAs
wikidata:Q96377889 n14:C69JV
dbp:wikiPageUsesTemplate
dbt:Infobox_medical_condition_(new) dbt:Reflist
dbp:deaths
rare, none due directly to the diseae
dbp:diagnosis
Histology of involved tissue
dbp:field
dbr:Oncology dbr:Hematology
dbp:frequency
extremely rare
dbo:abstract
Fibrin-associated diffuse large B-cell lymphoma (FA-DLBCL) is an extremely rare form of the diffuse large B-cell lymphomas (DLBCL). DLBCL are lymphomas in which a particular type of lymphocyte, the B-cell, proliferates excessively, invades multiple tissues, and often causes life-threatening tissue damage. DLBCL have various forms as exemplified by one of its subtypes, diffuse large B-cell lymphoma associated with chronic inflammation (DLBCL-CI). DLBCL-CI is an aggressive malignancy that develops in sites of chronic inflammation that are walled off from the immune system. In this protected environment, the B-cells proliferate excessively, acquire malignant gene changes, form tumor masses, and often spread outside of the protected environment. In 2016, the World Health Organization provisionally classified FA-DLBCL as a DLBCL-CI. Similar to DLBCL-CI, FA-DLBCL involves the proliferation of EBV-infected large B-cells in restricted anatomical spaces that afford protection from an individual's immune system. However, FA-DLBCL differs from DLBCL-CI in many other ways, including, most importantly, its comparatively benign nature. Some researchers have suggested that this disease should be regarded as a non-malignant or pre-malignant lymphoproliferative disorder rather than a malignant DLBCL-CI. FA-DLBCL is an Epstein–Barr virus-associated lymphoproliferative disease (EBV+ LPD), i.e. disease in which lymphocytes infected with the Epstein-Barr virus (EBV) proliferate excessively in one or more tissues. EBV infects ~95% of the world's population to cause no symptoms, minor non-specific symptoms, or infectious mononucleosis. The virus then enters a latency phase in which the infected individual becomes a lifetime asymptomatic carrier of the virus. Some weeks, months, years, or decades thereafter, a very small fraction of these carriers develop any one of various EBV-associated benign or malignant diseases. In FA-DLBCL as well as DLBCL-CI, EBV infects B-cells to promote their proliferation and thereby the development of either disease. FA-DLBCL most commonly develops within immunologically sequestered sites such as body cavities (e.g. pseudocysts) and foreign bodies (e.g. artificial heart valves) where fibrin, a breakdown product of the blood clotting factor, fibrinogen, has deposited. It is almost always discovered as an incidental finding in specimens taken from these sites when they are examined for reasons not directly related to the FA-DLBCL infiltrates. As reviewed in a publication of 2019, the disorder has been diagnoses in 47 individuals who are predominantly elderly males; it is almost uniformly amenable to various treatments and takes a benign course. However, the disease, when occurring within vascular or cardiac sites, does have a risk of being complicated by the development of embolisms due to the dislodgement of blood clots that travel through the vascular system to cause, e.g. strokes.
dbp:prognosis
good to excellent
prov:wasDerivedFrom
wikipedia-en:Fibrin-associated_diffuse_large_B-cell_lymphoma?oldid=1054174567&ns=0
dbo:wikiPageLength
15914
dbo:medicalDiagnosis
dbr:Histology
foaf:isPrimaryTopicOf
wikipedia-en:Fibrin-associated_diffuse_large_B-cell_lymphoma
Subject Item
wikipedia-en:Fibrin-associated_diffuse_large_B-cell_lymphoma
foaf:primaryTopic
dbr:Fibrin-associated_diffuse_large_B-cell_lymphoma